Injecting DNA into injured horse tendons and ligaments can cure lameness, new research involving scientists at Kazan Federal University, Moscow State Academy and The University of Nottingham has found.
The gene therapy technology was used in horses that had gone lame due to injury and within two to three weeks the horses were able to walk and trot. Within just two months they were back to full health, galloping and competing.
The study has big implications not just for the veterinary world but the future of human medicine – injuries like these are common in people as well as animals, not just in lameness but in other illnesses and diseases from the legs and arms through to the back and hips.
The new findings are the result of a partnership between the Kazan Federal University and Moscow State Academy of Veterinary Medicine and Biotechnology and Nottingham’s School of Veterinary Medicine and Science.
Dr Catrin Rutland, Assistant Professor of Anatomy and Developmental Genetics, led the work at Nottingham.
She said: “This pioneering study advances not only equine medicine but has real implications for how other species and humans are treated for lameness and other disorders in the future. The horses returned to full health after their injuries and did not have any adverse side effects. This is a very exciting medical innovation.”
The ground-breaking, international study, published in the academic journal Frontiers in Veterinary Science, demonstrated gene therapy using a combination of the Vascular Endothelial Growth Factor gene VEGF164, to enhance the growth of blood vessels and bone morphogenetic protein 2 (BMP2), which plays an important role in the development of bone and cartilage.
Both the genes were derived from horses, resulting in the biosynthesis of natural horse proteins in the treated animals. They were cloned into a single plasmid DNA, which is both biologically safe and unlikely to provoke an immune reaction from the body.
Current medical therapies have a relapse rate of 60 per cent and even the best regenerative medicine treatments have a 20 per cent relapse rate and take five to six months to work.
The new therapy is therefore very promising as it offers a much faster healing time and could significantly reduce relapse rates.
The results also showed that the tissue within the horses limbs has also fully recovered and 12 months after the revolutionary treatment the horses were completely fit, active and pain free.
Many medicines and treatments have adverse effects, but no side effects or bad reactions were seen in the horses treated.
Professor Albert Rizvanov, who led the study and is based at Kazan Federal University, said: “Advancing medicine, relieving pain and restoring function were the main aims of this study. We have shown that these are possible and within a much shorter time span than treatments available at the moment. In addition, we could use this type of therapy in other injuries and in many other situations ranging from fertility problems through to spinal cord injuries.
“Our next step is to secure more funding for an even larger trial to help more animals and improve and treat other disorders in the hope that one day we can routinely use this treatment around the world.”
The Latest on: Gene therapy
- Gene Editing Market Size, Share, Growth, Trend, Therapy, Technology To Achieve An Excellent 18.30% CAGR During The Forecast 2023on August 16, 2019 at 1:59 am
MRFR Offering The Reports Cover Key Developments In The Gene Editing Market As Organic And Inorganic Growth Strategies. Various Companies Are Focusing On Organic Growth Strategies Such As Product ...
- Immune-Activating Gene Therapy for Gliobastomaon August 15, 2019 at 3:19 pm
An inducible, tumor-localized gene therapy has been tested for the first time in glioblastoma patients. The two-part approach, which involves receiving an injection of an immune-activator gene into ...
- Amicus Should Be On Your Radar As It Makes Progress On Multiple Fronts Using Gene Therapyon August 15, 2019 at 9:21 am
Amicus was able to achieve positive interim results from a phase 1/2 study using AAV-CLN6 gene therapy to treat patients with Batten disease. Another gene therapy, known as AT-GAA, is currently ...
- Novartis shuffles AveXis executive team in wake of gene therapy data manipulation scandalon August 14, 2019 at 2:32 pm
Swiss drugmaker Novartis has shaken up the management at its gene therapy subsidiary in the wake of the data manipulation scandal that rocked the company last week. The subsidiary, AveXis, said ...
- Novartis ousted top scientists over manipulation of data for gene therapyon August 14, 2019 at 9:41 am
Novartis dismissed the top two scientists at its gene therapy division shortly after CEO Vas Narasimhan learned of internal data falsification that has since snowballed into a damaging scandal, a ...
- Philadelphia gene therapy startup targeting heart disease raises $11Mon August 14, 2019 at 8:53 am
A Philadelphia biopharmaceutical company spun out of Temple University that is developing gene therapy-based treatments for cardiovascular disease has raised $11 million in a venture capital financing ...
- Renovacor Closes $11 Million Series A Financing to Advance First Gene Therapy for a Rare Cardiovascular Diseaseon August 14, 2019 at 5:25 am
– Funding supports preclinical development through IND submission for its BAG3 gene therapy, the first gene replacement product for genetic forms of dilated cardiomyopathy – Company announces ...
- Sangamo: Lead Gene Therapy Program Moving Into Phase 3on August 13, 2019 at 2:51 pm
Clinical program SB-525 is in the process of advancing to a registrational Phase 3. Partner Pfizer has accelerated a lead-in study by leveraging their Spark hemophilia B trial. The next gene ...
- In move to establish leading edge, Durham gene therapy company acquires U.K. operationon August 13, 2019 at 5:50 am
Making use of its massive private investment haul earlier this year, one of the Triangle's leading gene therapy companies has acquired a U.K. operation, which it believes rounds out its best-in-class ...
- AskBio Acquires Synpromics Ltd. and Expands its Gene Therapy Technology Portfolioon August 13, 2019 at 1:31 am
Synpromics to operate as a wholly owned subsidiary; the two companies bring together pioneering technology to increase efficacy of gene therapeutics RESEARCH TRIANGLE PARK, N.C., Aug. 13, 2019 ...
via Google News and Bing News